Analyst Ratings For Quest Diagnostics Inc (NYSE:DGX)
Today, Bank of America initiated coverage on Quest Diagnostics Inc (NYSE:DGX) with a Buy.
There are 11 Buy Ratings, 7 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Quest Diagnostics Inc (NYSE:DGX) is Buy with a consensus target price of $111.50 per share, a potential 8.91% upside.
Some recent analyst ratings include
- 10/19/2018-Quest Diagnostics Inc (NYSE:DGX) has coverage initiated with a Buy rating
- 7/10/2018-Quest Diagnostics Inc (NYSE:DGX) gets upgraded to Outperform by Evercore ISI with a price target of $103.00
- 6/27/2018-Quest Diagnostics Inc (NYSE:DGX) gets downgraded to Hold by MED
- 6/27/2018-Quest Diagnostics Inc (NYSE:DGX) gets downgraded to Hold by Deutsche Bank with a price target of $108.00
- 6/25/2018-Quest Diagnostics Inc (NYSE:DGX) gets upgraded to Overweight by Barclays with a price target of $130.00
Recent Insider Trading Activity For Quest Diagnostics Inc (NYSE:DGX)
Quest Diagnostics Inc (NYSE:DGX) has insider ownership of 1.79% and institutional ownership of 86.16%.
- On 7/10/2018 Everett Cunningham, SVP, sold 40,328 with an average share price of $112.00 per share and the total transaction amounting to $4,516,736.00.
- On 7/2/2018 Everett Cunningham, SVP, sold 68,069 with an average share price of $109.67 per share and the total transaction amounting to $7,465,127.23.
- On 5/29/2018 Jeffrey M Leiden, Director, sold 1,644 with an average share price of $105.61 per share and the total transaction amounting to $173,622.84.
- On 5/25/2018 Mark Guinan, Insider, sold 61,533 with an average share price of $105.71 per share and the total transaction amounting to $6,504,653.43.
- On 5/25/2018 Stephen H Rusckowski, Chairman, sold 168,490 with an average share price of $107.00 per share and the total transaction amounting to $18,028,430.00.
- On 3/8/2018 Jon R Cohen, SVP, sold 83,669 with an average share price of $104.20 per share and the total transaction amounting to $8,718,309.80.
- On 3/5/2018 Catherine T Doherty, SVP, sold 5,556 with an average share price of $101.00 per share and the total transaction amounting to $561,156.00.
About Quest Diagnostics Inc (NYSE:DGX)
Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Recent Trading Activity for Quest Diagnostics Inc (NYSE:DGX)
Shares of Quest Diagnostics Inc closed the previous trading session at 102.38 up +0.0100 0.0098% with 103.61 shares trading hands.